WO2012013850A3 - Compound for treating neurodegenerative diseases, cognitive deficiencies and/or dementia - Google Patents

Compound for treating neurodegenerative diseases, cognitive deficiencies and/or dementia Download PDF

Info

Publication number
WO2012013850A3
WO2012013850A3 PCT/ES2011/070539 ES2011070539W WO2012013850A3 WO 2012013850 A3 WO2012013850 A3 WO 2012013850A3 ES 2011070539 W ES2011070539 W ES 2011070539W WO 2012013850 A3 WO2012013850 A3 WO 2012013850A3
Authority
WO
WIPO (PCT)
Prior art keywords
compound
dementia
neurodegenerative diseases
treating neurodegenerative
cognitive deficiencies
Prior art date
Application number
PCT/ES2011/070539
Other languages
Spanish (es)
French (fr)
Other versions
WO2012013850A2 (en
Inventor
Javier Santos Burgos Muñoz
Maria del Carmen Ramos Martín
Saleta SIERRA ÁVILA
Beatriz SUÁREZ GONZÁLEZ
Juan María Alfaro Sánchez
Original Assignee
Neuron Biopharma, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuron Biopharma, S.A. filed Critical Neuron Biopharma, S.A.
Publication of WO2012013850A2 publication Critical patent/WO2012013850A2/en
Publication of WO2012013850A3 publication Critical patent/WO2012013850A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the use of a gemifloxacin compound for the treatment of neurodegenerative diseases, mild cognitive impairment, cognitive deficiencies, dementia, diseases associated with ageing and pathological processes associated with age and progeria and, in particular, Alzheimer's disease, owing to the discovery of novel properties intrinsic to said compound.
PCT/ES2011/070539 2010-07-26 2011-07-22 Compound for treating neurodegenerative diseases, cognitive deficiencies and/or dementia WO2012013850A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP201001078 2010-07-26
ES201001078A ES2373598B1 (en) 2010-07-26 2010-07-26 COMPOSITE TO TREAT NEURODEGENERATIVE DISEASES, COGNITIVE DEFICITS AND / OR DEMENCIES.

Publications (2)

Publication Number Publication Date
WO2012013850A2 WO2012013850A2 (en) 2012-02-02
WO2012013850A3 true WO2012013850A3 (en) 2012-03-22

Family

ID=45497530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2011/070539 WO2012013850A2 (en) 2010-07-26 2011-07-22 Compound for treating neurodegenerative diseases, cognitive deficiencies and/or dementia

Country Status (2)

Country Link
ES (1) ES2373598B1 (en)
WO (1) WO2012013850A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2680842A4 (en) * 2011-03-02 2014-10-29 Bionomics Ltd Methods of treating a disease or condition of the central nervous system

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262071B1 (en) * 1999-06-29 2001-07-17 Smithkline Beecham Corporation Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria
US20010014670A1 (en) * 1998-01-09 2001-08-16 Brian J. Balin Treatment and diagnosis of alzheimer's disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010014670A1 (en) * 1998-01-09 2001-08-16 Brian J. Balin Treatment and diagnosis of alzheimer's disease
US6262071B1 (en) * 1999-06-29 2001-07-17 Smithkline Beecham Corporation Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AMARANTE, G.W. ET AL.: "Mechanism and synthesis of pharmacologically active quinolones from Morita-Baylis-Hillman adducts", TETRAHEDRON, vol. 66, 2010, pages 4370 - 4376, XP027050806 *

Also Published As

Publication number Publication date
ES2373598B1 (en) 2012-11-14
WO2012013850A2 (en) 2012-02-02
ES2373598A1 (en) 2012-02-07

Similar Documents

Publication Publication Date Title
EP3715345A3 (en) Preparation of lfa-1 inhibitor and polymorph thereof
EP2519234A4 (en) Anaplerotic therapy for alzheimer's disease and the aging brain
WO2013033037A3 (en) Novel antiprion compounds
MY156274A (en) COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION
WO2015095337A3 (en) PYRAZOLO[1,5-a]PYRIMIDINECARBOXAMIDE DERIVATIVES FOR TREATING COGNITIVE IMPAIRMENT
GB0910003D0 (en) Novel compounds for the treatment of neurodegenerative diseases
WO2014028461A3 (en) Treatment and diagnosis of melanoma
WO2012040641A3 (en) Compounds for treating neurodegenerative diseases
NZ626937A (en) Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors
PL1940817T3 (en) Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
WO2011141823A3 (en) Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
WO2010059241A3 (en) Treatment of amyotrophic lateral sclerosis
EP2977452A3 (en) Methods of treatment and prevention of neurodegenerative diseases and disorders
EA201390704A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
IN2012DN05186A (en)
IL216084A0 (en) 2,4-diaminopyrimidines for the treatment of diseases characterised by excessive or abnormal cell proliferation
WO2014071067A3 (en) Treatment and diagnosis of colon cancer
WO2011159693A3 (en) Oral treatment of digital ischemic lesions
WO2009115252A3 (en) Substituted pyrazolamides and the use thereof
EA201390876A1 (en) METALLIC ENZYME INHIBITING COMPOUNDS
WO2011160974A3 (en) Statin derivates and intermediates for their production
WO2011073370A3 (en) Use of 2,3-dihydroxypropyl dodecanoate for treating seborrhea
IN2014DN09826A (en)
WO2012013850A3 (en) Compound for treating neurodegenerative diseases, cognitive deficiencies and/or dementia
WO2008030391A3 (en) Difluorinated piperidines for treatment of alzheimer's disease and related conditions

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11811877

Country of ref document: EP

Kind code of ref document: A2